Figure 1 | Cell Death & Disease

Figure 1

From: miRNA-558 promotes gastric cancer progression through attenuating Smad4-mediated repression of heparanase expression

Figure 1

miR-558 facilitates the HPSE expression in gastric cancer cells. (a) Scheme of potential target sites of Smad4 (−2277/−2287) and miR-558 (−2314/−2332) within the promoter of HPSE. (b) Real-time quantitative RT-PCR assay showing the miR-558 levels in primary stomach epithelial HPSEC cells, SV40-immortalized normal gastric epithelial GES-1 cells and gastric cancer cell lines (MKN-45, SGC-7901, AGS and MKN-28). (c) and (d) Real-time quantitative RT-PCR and western blot assays indicating the expression of miR-558, HPSE and VEGF in gastric cancer cells stably transfected with empty vector (mock) or miR-558 precursor. (e) and (f) Real-time quantitative RT-PCR and western blot assays showing the expression of miR-558, HPSE and VEGF in gastric cancer cells transfected with negative control inhibitor (anti-NC, 100 nmol/l) or anti-miR-558 inhibitor (100 nmol/l). (g) and (h) Real-time quantitative RT-PCR assay indicating the transcript levels of HPSE and VEGF in gastric cancer cells transfected with mock, miR-558 precursor, anti-NC (100 nmol/l) or anti-miR-558 inhibitor (100 nmol/l). (i) and (j) Nuclear run-on assay showing the nascent HPSE transcript levels in gastric cancer cells transfected with mock, miR-558 precursor, anti-NC (100 nmol/l) or anti-miR-558 inhibitor (100 nmol/l). *P<0.01 versus HPSEC, mock or anti-NC

Back to article page